by Nephrology Knowledge into Practice Podcast
A summary of new trial data, guideline recommendations and expert opinion across kidney care, run by Nephrology Knowledge into Practice (https://nephrology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe. This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.
Language
🇺🇲
Publishing Since
3/1/2022
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
December 5, 2022
<p>In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations.</p> <p>In this episode we speak to Dr Richard Glassock, member of the work group, to hear his insights on the key takeaways from the guideline, and what has changed in this iteration.</p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.</p> <p><strong>Reference:</strong></p> <p><a href="https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf" rel="noreferrer noopener" target="_blank"><u>KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. </u></a></p> <p><strong>Disclosures:</strong></p> <p>Dr Richard Glassock declares the following:</p> <p>Stock Ownership - Reata Pharmaceuticals</p> <p>Speakers Bureau - Aurinia</p> <p>Advisory Board - Alexion, Bio-Cryst, Novartis, Otsuka, RenaSight, Travere, Vertex</p> <p>Consultant - Alexion, Arrowhead, Aurinia, Bio-Cryst, Calliditas, Chinook, Equillium, Horizon Pharma, Ionis, Midornid, Nephro-Sys, Omeros, River3Renal, Therini Bio, Travere, Vera Pharmaceuticals</p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.</p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.</p> <p>The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.</p> <p>This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.</p> <p>Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of FSGS.</p> <p><strong>Funding:</strong></p> <p>This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.</p>
November 22, 2022
<p>In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. </p> <p>In this episode we speak to Professor Jürgen Floege, co-chair of the work group, to hear his insights on the key takeaways, and the clinical data that has emerged since the guideline update was made. </p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. </p> <p><a href="https://nephrology.knowledgeintopractice.com/learning/podcast/episodes/ig-an-kdigo-2021-guideline/pre-assessment" target="_blank"><strong>References available here</strong></a></p> <p><strong>Disclosures:</strong> </p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. </p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. </p> <p>The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. </p> <p>This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. </p> <p>Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. </p> <p><strong>Funding: </strong> </p> <p>This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education. </p>
October 20, 2022
<p>Current standard of care for IgA nephropathy (IgAN) involves optimized supportive care, antihypertensives, and dietary and lifestyle modifications. Despite these interventions, ~30% of patients progress to end stage renal disease. Recent approvals of delayed-release budesonide for IgAN and dapagliflozin for chronic kidney disease, and further investigational agents have the potential to alter the treatment landscape for IgAN.</p> <p>In this episode, Professor Rosanna Coppo offers her expert insight into the potential clinical implications of current and investigational therapies, both now and in the future.</p> <p>By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.</p> <p><strong>References:</strong></p> <p><a href="https://nephrology.knowledgeintopractice.com/learning/podcast/episodes/ig-an-current-and-future-therapies/listen" target="_blank">References available here</a></p> <p>This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.</p> <p><strong>Disclosures:</strong></p> <p>Prof. Rosanna Coppo has no disclosures to declare.</p> <p>Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.</p> <p>The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.</p> <p>The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.</p> <p>This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.</p> <p>Discussion of Off-Label, Investigational or Experimental Drug Use: Atrasentan, C5 inhibitor RNA therapies, eculizumab, empagliflozin, iptacopan, narsoplimab, ravulizumab, and sparsentan are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Sparsentan is also discussed in the context of the treatment of focal segmental glomerulosclerosis.</p> <p><strong>Funding:</strong></p> <p>This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.</p>
Discover related shows you might enjoy
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
A summary of new trial data, guideline recommendations and expert opinion across kidney care, run by Nephrology Knowledge into Practice (https://nephrology.knowledgeintopractice.com), featuring interviews with leading experts from across the globe.
This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Yes, this podcast regularly features guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
